Sailish Honap1, Desmond Chee2, Thomas P Chapman3, Mehul Patel4, Alexandra J Kent4, Shuvra Ray1, Esha Sharma1, James Kennedy3, Sarah Cripps5, Alissa Walsh3, James R Goodhand2, Tariq Ahmad2, Jack Satsangi3, Peter M Irving1,6, Nicholas A Kennedy2. 1. IBD Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, UK. 2. Department of Gastroenterology, Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK. 3. Translational Gastroenterology Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. 4. Department of Gastroenterology, King's College Hospital NHS Foundation Trust, London, UK. 5. Department of Pharmacy, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. 6. School of Immunology and Microbial Sciences, King's College London, London, UK.
Abstract
BACKGROUND: Tofacitinib is a partially selective Janus kinase inhibitor approved for the treatment of refractory moderate to severe ulcerative colitis [UC]. We sought to define the effectiveness and adverse effects of tofacitinib in a real-world cohort. METHODS: We conducted a retrospective observational cohort study of 134 patients with UC [64% male; median age 37 years [range 16-81]; 83% of patients had previously received at least one biologic] treated with tofacitinib from October 2018 to October 2019 in four UK centres. Disease activity was assessed using the Simple Clinical Colitis Activity Index [SCCAI] or partial Mayo score [PMS], depending on study site. Response and remission were defined as a reduction in SCCAI or PMS of ≥3and SCCAI ≤2 or a PMS ≤1, respectively. RESULTS: Overall, 74% (88/119; 95 confidence interval [CI] 65-81%] patients responded to tofacitinib at Week 8 and steroid-free remission was observed in 44% [47/108; 95% CI 3453%] patients at Week 26. Primary non-response was independently associated with younger age [p = 0.014] and higher C-reactive protein [CRP] levels at baseline [p = 0.004]. Only 23% [3/13] of patients who continued tofacitinib in the setting of primary non-response were in steroid-free remission at Week 26. Prior biologic exposure did not influence response or remission rates. Dose escalation, however, recaptured response in approximately half of patients who had lost response. Dyslipidaemia was observed in 20% [27/134; 95% CI 1428%] of patients, but adverse events necessitating drug withdrawal were uncommon and no venous thromboembolic events occurred. CONCLUSIONS: In this multicentre real-world cohort, tofacitinib was well tolerated and clinically effective in a treatment-refractory UC population.
BACKGROUND:Tofacitinib is a partially selective Janus kinase inhibitor approved for the treatment of refractory moderate to severe ulcerative colitis [UC]. We sought to define the effectiveness and adverse effects of tofacitinib in a real-world cohort. METHODS: We conducted a retrospective observational cohort study of 134 patients with UC [64% male; median age 37 years [range 16-81]; 83% of patients had previously received at least one biologic] treated with tofacitinib from October 2018 to October 2019 in four UK centres. Disease activity was assessed using the Simple Clinical Colitis Activity Index [SCCAI] or partial Mayo score [PMS], depending on study site. Response and remission were defined as a reduction in SCCAI or PMS of ≥3and SCCAI ≤2 or a PMS ≤1, respectively. RESULTS: Overall, 74% (88/119; 95 confidence interval [CI] 65-81%] patients responded to tofacitinib at Week 8 and steroid-free remission was observed in 44% [47/108; 95% CI 3453%] patients at Week 26. Primary non-response was independently associated with younger age [p = 0.014] and higher C-reactive protein [CRP] levels at baseline [p = 0.004]. Only 23% [3/13] of patients who continued tofacitinib in the setting of primary non-response were in steroid-free remission at Week 26. Prior biologic exposure did not influence response or remission rates. Dose escalation, however, recaptured response in approximately half of patients who had lost response. Dyslipidaemia was observed in 20% [27/134; 95% CI 1428%] of patients, but adverse events necessitating drug withdrawal were uncommon and no venous thromboembolic events occurred. CONCLUSIONS: In this multicentre real-world cohort, tofacitinib was well tolerated and clinically effective in a treatment-refractory UC population.
Authors: Shreya Gopalakrishnan; Marianne Doré Hansen; Helene Kolstad Skovdahl; Ingrid Aass Roseth; Atle van Beelen Granlund; Ann Elisabet Østvik; Ingunn Bakke; Arne Kristian Sandvik; Torunn Bruland Journal: Front Immunol Date: 2022-05-17 Impact factor: 8.786
Authors: Laura A Lucaciu; Nathan Constantine-Cooke; Nikolas Plevris; Spyros Siakavellas; Lauranne A A P Derikx; Gareth-Rhys Jones; Charles W Lees Journal: Therap Adv Gastroenterol Date: 2021-12-23 Impact factor: 4.409
Authors: Vito Annese; Rahul Nathwani; Maryam Alkhatry; Ahmad Al-Rifai; Sameer Al Awadhi; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Mazen S Taha; Jimmy K Limdi Journal: Therap Adv Gastroenterol Date: 2021-12-22 Impact factor: 4.409
Authors: Jeffrey A Berinstein; Jessica L Sheehan; Michael Dias; Elliot M Berinstein; Calen A Steiner; Laura A Johnson; Randolph E Regal; John I Allen; Kelly C Cushing; Ryan W Stidham; Shrinivas Bishu; Jami A R Kinnucan; Shirley A Cohen-Mekelburg; Akbar K Waljee; Peter D R Higgins Journal: Clin Gastroenterol Hepatol Date: 2021-05-25 Impact factor: 11.382